Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies

Biomedical Chromatography

Volumn 21, Issue 2, 2007, Pages 184-189

  Yeo, Pauline ^a   Xin, Liu ^a   Goh, Evelyn ^a   New, Lee Sun ^a   Zeng, Peizi ^a   Wu, Xiaofeng ^a   Vankatesh, P ^a   Kantharaj, Ethirajulu ^a  

^a Singapore Science Park II   (Singapore)

Author keywords

EX 2; HDAC inhibitors; HPLC tandem mass spectrometry assay; Mouse plasma; Pharmacokinetics

Indexed keywords

CALIBRATION; CLINICAL RESEARCH; FATTY ACIDS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAMMALS; MASS SPECTROMETRY; SYNTHESIS (CHEMICAL);

EX-2; HEXANOIC ACIDS; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; HISTONE DEACETYLASE INHIBITOR; HPLC-TANDEM MASS SPECTROMETRY ASSAY; MICE PLASMA; PHARMACOKINETIC PARAMETERS; PHARMACOKINETIC STUDIES; TANDEM MASS SPECTROMETRY; TANDEM-MASS SPECTROMETRY;

PHARMACOKINETICS;

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 6 (3 BENZOYLUREIDO)HEXANOIC ACID HYDROXYAMIDE; AMIDOHYDROLASE INHIBITOR; CARBAMAZEPINE; EX 2; HISTONE DEACETYLASE INHIBITOR; LBH 589; UNCLASSIFIED DRUG; VORINOSTAT;

ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; QUALITY CONTROL; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 33847043595     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.734     Document Type: Article

References (8)

1. Davies B and Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 1993; 10: 1093-1095.
2. Gibaldi M and Perrier D. Pharmacokinetics, 2nd edn. Marcel Dekker: New York, 1982; 409-417.
3. Hassig CA and Schreiber SL. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Current Opinion in Chemical Biology 1997; 1: 300-308.
4. Kelly WK and Marks PA. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nature Clinical Practice Oncology 2005; 2: 150-157.
5. Liu RJ, Nagy L, Inoue S, Shao W, Miller WH and Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-814.
6. Pikul S, Ohler NE, Ciszewski G, Laufersweiler MC, Almstead NG, De B, Natchus MG, Hsieh LC, Janusz MJ, Peng SX, Branch TM, King SL, Taiwo YO and Mieling GE. Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. Journal of Medicinal Chemistry 2001; 2: 2499-2502.
7. Strahl BD and Allis CD. The language of covalent histone modifications. Nature 2000; 6: 403.
8. US FDA. Guidance for Industry, Bioanalytical Method Validation. US FDA, CDER: New York, May 2001.